The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Generation IM’s Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled A Phase ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...